Skip to main content
Clinical Trials/NCT04079114
NCT04079114
Terminated
Not Applicable

Post Market Clinical Follow-Up Study of the Zimmer Stafit Acetabular System. A Multicenter, Prospective, Non-controlled Study

Zimmer Biomet0 sites166 target enrollmentApril 28, 2011

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Osteoarthritis, Hip
Sponsor
Zimmer Biomet
Enrollment
166
Primary Endpoint
Dislocation Rate
Status
Terminated
Last Updated
5 years ago

Overview

Brief Summary

This study is a Post Market Clinical Follow up study to fulfil the post market surveillance obligations according to Medical Device Directive and European Medical Device Vigilance System (MEDDEV) 2.12-2. The data collected from this study will serve the purpose of confirming safety and performance of the Zimmer Stafit Acetabular System.

Detailed Description

The objective of this study is to obtain implant survival and outcome data on the Stafit Acetabular System by analysis of standard scoring systems, radiographs, and adverse event records. Data will be used to monitor pain, mobility, dislocation rate and implant survival, and to confirm the long-term safety and performance of the Stafit Acetabular System in primary total hip arthroplasty. The study design is a multi-center, prospective, non-controlled, consecutive cohort post market clinical follow-up study, involving orthopedic surgeons skilled in total hip arthroplasty procedures and experienced with the Stafit Acetabular System.

Registry
clinicaltrials.gov
Start Date
April 28, 2011
End Date
July 15, 2019
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Males and females
  • Patients suffering from severe hip pain and disability requiring a primary total hip arthroplasty.
  • 18 years minimum
  • Patients able to participate in a follow-up program based upon physical examination and medical history
  • Patients who have provided written informed consent by signing the Patient Informed Consent Form.

Exclusion Criteria

  • Patients who are unwilling or unable to give informed consent, or to comply with the follow-up program
  • Known pregnancy
  • Revision hip arthroplasty

Outcomes

Primary Outcomes

Dislocation Rate

Time Frame: 2 years

Assessed by counting the number of implant dislocations

Implant Survival

Time Frame: 3 years postoperatively, due to early study termination

Represents the implants that survived by counting the number of implants revised.

Secondary Outcomes

  • Evaluation of Pain and Functional Performance Determined by the Harris Hip Score(3 years postoperatively, due to early study termination)
  • Confirmation of Safety Based on Complications(3 years postoperatively, due to early study termination)

Similar Trials